Profusa (NASDAQ:PFSA) Announces Earnings Results

Profusa (NASDAQ:PFSA) issued its quarterly earnings data on Friday. The company reported ($2.05) earnings per share for the quarter, FiscalAI reports.

Profusa Stock Up 3.7%

NASDAQ PFSA opened at $0.45 on Friday. The company has a market cap of $1.96 million, a P/E ratio of 0.00 and a beta of 0.47. The company’s fifty day moving average is $0.70. Profusa has a 12 month low of $0.40 and a 12 month high of $180.00.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFSA. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Friday, March 27th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.